Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Graft-versus-host Disease (GVHD) Clinical Trial

Official title:
Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD

Status Approved for marketing

Clinical Trial Summary

To provide ruxolitinib through an expanded access to treat a single patient with cGVHD

n/a

See also
Status	Clinical Trial	Phase
Completed	`NCT03112603` - A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)	Phase 3
Completed	`NCT03139604` - GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease	Phase 3
Completed	`NCT02953678` - A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)	Phase 2
Completed	`NCT02614612` - Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD	Phase 1
Approved for marketing	`NCT03147742` - An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant